After Frontline T-DXd: How Should HER2+ Disease Be Sequenced Next?

A common fear: “If we use T-DXd first… what’s left?”

The fear of exhausting options shouldn’t compromise frontline efficacy. Starting with the most potent ADC still allows for a strategic sequence of diverse mechanisms of action and CNS-directed therapies. This clip explores why a frontline win is the priority and how the toolkit remains robust for later lines of care.